共 50 条
Early Initiation of Antitumor Necrosis Factor Therapy Reduces Postoperative Recurrence of Crohn's Disease Following Ileocecal Resection
被引:17
作者:
Axelrad, Jordan E.
[1
]
Li, Terry
[2
]
Bachour, Salam P.
[3
]
Nakamura, Takahiro, I
[4
]
Shah, Ravi
[3
]
Sachs, Michael C.
[5
]
Chang, Shannon
[1
]
Hudesman, David P.
[1
]
Holubar, Stefan D.
[6
]
Lightner, Amy L.
[6
]
Barnes, Edward L.
[7
]
Cohen, Benjamin L.
[8
]
Rieder, Florian
[8
]
Esen, Eren
[9
]
Remzi, Feza
[9
]
Regueiro, Miguel
[8
]
Click, Benjamin
[8
]
机构:
[1] NYU, Dept Med, Divison Gastroenterol, Grossman Sch Med, New York, NY 10016 USA
[2] NYU, Dept Med, Grossman Sch Med, New York, NY 10016 USA
[3] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Cleveland, OH 44106 USA
[4] Univ Vermont, Dept Med, Divison Gastroenterol, Larner Coll Med, Burlington, VT USA
[5] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[6] Cleveland Clin, Dept Colorectal Surg, Cleveland, OH 44106 USA
[7] UNC Sch Med, Dept Med, Div Gastroenterol, Chapel Hill, NC USA
[8] Cleveland Clin, Dept Gastroenterol Hepatol & Nutr, Cleveland, OH 44106 USA
[9] NYU, Dept Surg, Grossman Sch Med, New York, NY 10016 USA
关键词:
Crohn's disease;
postoperative recurrence;
resection;
biologic therapy;
MAGNETIC-RESONANCE ENTEROGRAPHY;
COMPUTED-TOMOGRAPHY;
ILEOCOLIC RESECTION;
METAANALYSIS;
ADALIMUMAB;
RISK;
PREVENTION;
MANAGEMENT;
D O I:
10.1093/ibd/izac158
中图分类号:
R57 [消化系及腹部疾病];
学科分类号:
摘要:
Lay Summary Postoperative recurrence of Crohn's disease is common after ileocecal resection. In this dual-center study, early initiation of an anti-TNF agent within 4 weeks following an ileocecal resection was associated with a reduction in postoperative recurrence of Crohn's disease. Background Postoperative recurrence (POR) of Crohn's disease (CD) is common after surgical resection. We aimed to compare biologic type and timing for preventing POR in adult CD patients after ileocecal resection (ICR). Methods We performed a retrospective cohort study of CD patients who underwent an ICR at 2 medical centers. Recurrence was defined by endoscopy (>= i2b Rutgeerts score) or radiography (active inflammation in neoterminal ileum) and stratified by type and timing of postoperative prophylactic biologic within 12 weeks following an ICR (none, tumor necrosis factor antagonists [anti-TNF], vedolizumab, and ustekinumab). Results We identified 1037 patients with CD who underwent an ICR. Of 278 (26%) who received postoperative prophylaxis, 80% were placed on an anti-TNF agent (n = 223) followed by ustekinumab (n = 28, 10%) and vedolizumab (n = 27, 10%). Prophylaxis was initiated in 35% within 4 weeks following an ICR and in 65% within 4 to 12 weeks. After adjusting for factors associated with POR, compared with no biologic prophylaxis, the initiation of an anti-TNF agent within 4 weeks following an ICR was associated with a reduction in POR (adjusted hazard ratio, 0.61; 95% CI, 0.40-0.93). Prophylaxis after 4 weeks following an ICR or with vedolizumab or ustekinumab was not associated with a reduction in POR compared with those who did not receive prophylaxis. Conclusion Early initiation of an anti-TNF agent within 4 weeks following an ICR was associated with a reduction in POR. Vedolizumab or ustekinumab, at any time following surgery, was not associated with a reduction in POR, although sample size was limited.
引用
收藏
页码:888 / 897
页数:10
相关论文